StockFacets
About
Sign-up
Sign-in
Earnings Calendar
Prices are updated after-hours
Published
Previous years
34
This year
4
Publishing Date
2024 - 02 - 22
1
2024 - 02 - 06
1
2024 - 02 - 02
1
2024 - 01 - 25
1
2023 - 11 - 21
1
2023 - 11 - 01
1
2023 - 08 - 21
1
2023 - 06 - 27
1
2023 - 06 - 15
1
2023 - 06 - 08
1
2023 - 05 - 15
1
2023 - 03 - 31
1
2023 - 03 - 11
1
2023 - 01 - 12
1
2022 - 12 - 08
2
2022 - 08 - 03
1
2022 - 07 - 11
1
2022 - 05 - 26
1
2022 - 05 - 03
2
2022 - 03 - 25
2
2022 - 03 - 14
1
2022 - 01 - 18
1
2021 - 11 - 09
1
2021 - 09 - 20
1
2021 - 09 - 17
1
2021 - 08 - 05
2
2021 - 07 - 28
1
2021 - 06 - 28
1
2021 - 06 - 07
1
2021 - 05 - 20
1
Sector
Health technology
34
Manufacturing
4
Tags
Alliances
16
Antibody
7
Application
11
Approval
20
Asia
14
Biotech
6
Biotech-bay
10
Biotech-beach
17
Cabometyx
7
Cancer
34
Cell carcinoma
7
Children
7
Clinical-trials-phase-ii
10
Clinical-trials-phase-iii
23
Collaboration
15
Covid
11
Covid-19
10
Disease
32
Drug
29
Earnings
23
Events
8
Expected
7
Fda
16
Financial
17
Financial results
13
Gene therapies
6
Gene therapy
6
Genetown
22
Global
51
Growth
29
Hereditary angioedema
8
Injection
6
Japan
7
License
13
Liver
16
Market
84
Money
11
N/a
184
Nivolumab
6
Partnership
6
People
7
Pharmaceutical
17
Phase 2
6
Phase 3
19
Positive
14
Product-news
10
Rare
11
Reach
11
Renal
7
Report
45
Research
41
Results
58
Sars-cov-2
6
Study
8
Takhzyro
7
Therapeutics
37
Therapy
42
Treatment
49
Trial
36
Vaccine
27
Entities
Abbott laboratories
48
Abbvie inc.
53
Accuray incorporated
26
Agenus inc.
21
Agilent technologies, inc.
27
Amgen inc.
91
Anixa biosciences, inc.
48
Astellas pharma inc
49
Astrazeneca plc
144
Aveo pharmaceuticals, inc.
24
Becton, dickinson and company
26
Beigene, ltd.
58
Biocept, inc.
31
Biontech se
21
Blueprint medicines corporation
27
Briacell therapeutics corp.
50
Bristol-myers squibb company
107
Castle biosciences, inc.
28
Clovis oncology, inc.
33
Eli lilly and company
139
Exact sciences corporation
56
Exelixis, inc.
43
G1 therapeutics, inc.
27
Genprex, inc.
26
Gilead sciences, inc.
59
Glaxosmithkline plc
54
Guardant health, inc.
53
Hologic, inc.
32
Hoth therapeutics, inc.
29
Illumina, inc.
68
Immunitybio inc
29
Immunogen, inc.
25
Immutep limited
34
Incyte corporation
57
Invitae corporation
25
Jaguar health, inc.
36
Johnson & johnson
138
Karyopharm therapeutics inc.
27
Lantern pharma inc.
24
Lixte biotechnology holdings inc.
22
Merck & company, inc.
75
Merus n.v.
24
Mirati therapeutics, inc.
32
Myriad genetics, inc.
50
Nanostring technologies, inc.
22
Natera, inc.
38
Novartis ag
106
Novocure limited
30
Oncolytics biotech inc.
41
Orange
138
Pds biotechnology corporation
34
Pfizer, inc.
66
Qiagen n.v.
31
Regeneron pharmaceuticals, inc.
42
Sanofi
215
Seagen inc.
55
Takeda pharmaceutical company limited
34
Thermo fisher scientific inc
51
Veracyte, inc.
45
Verastem, inc.
25
Symbols
ABBV
4
ADCT
1
ALPMF
4
ALPMY
4
AMGN
4
AZN
8
AZNCF
7
BMY
8
BNTX
1
EXEL
17
GILD
1
GLAXF
5
GMAB
1
GNMSF
1
GSK
6
HCM
2
IMGN
1
JAZZ
1
JNJ
4
LLY
7
NVS
8
NVSEF
7
OBSV
1
PFE
3
SNY
4
SNYNF
4
STRO
1
TAK
34
TEVJF
2
TPTX
1
UCBJF
2
UCBJY
2
VRTX
1
ZYME
1
Exchanges
Nasdaq
29
Nyse
34
Crawled Date
2024 - 02 - 22
1
2024 - 02 - 07
1
2024 - 02 - 02
1
2024 - 01 - 25
1
2023 - 11 - 21
1
2023 - 11 - 01
1
2023 - 08 - 21
1
2023 - 06 - 27
1
2023 - 06 - 15
1
2023 - 06 - 08
1
2023 - 05 - 15
1
2023 - 03 - 31
1
2023 - 03 - 11
1
2023 - 01 - 12
1
2022 - 12 - 08
2
2022 - 08 - 03
1
2022 - 07 - 11
1
2022 - 05 - 27
1
2022 - 05 - 03
2
2022 - 03 - 25
2
2022 - 03 - 15
1
2022 - 01 - 19
1
2021 - 11 - 09
1
2021 - 09 - 20
1
2021 - 09 - 17
1
2021 - 08 - 05
2
2021 - 07 - 28
1
2021 - 06 - 28
1
2021 - 06 - 07
1
2021 - 05 - 20
1
Crawled Time
00:00
2
01:00
5
02:00
1
04:20
1
05:00
1
08:00
1
09:00
1
10:00
1
11:00
1
12:15
1
13:00
2
14:00
2
14:20
1
15:15
2
17:00
2
18:00
4
19:00
1
22:00
4
23:00
1
Source
www.biospace.com
19
www.globenewswire.com
3
www.prnewswire.com
12
Sort by:
after hours % change
|
delayed % change
|
gain open
|
gain high
|
gain close
|
publishing date
(GMT-12:00) International Date Line West
(GMT-11:00) American Samoa
(GMT-11:00) Midway Island
(GMT-10:00) Hawaii
(GMT-09:00) Alaska
(GMT-08:00) Pacific Time (US & Canada)
(GMT-08:00) Tijuana
(GMT-07:00) Arizona
(GMT-07:00) Chihuahua
(GMT-07:00) Mazatlan
(GMT-07:00) Mountain Time (US & Canada)
(GMT-06:00) Central America
(GMT-06:00) Central Time (US & Canada)
(GMT-06:00) Guadalajara
(GMT-06:00) Mexico City
(GMT-06:00) Monterrey
(GMT-06:00) Saskatchewan
(GMT-05:00) Bogota
(GMT-05:00) Eastern Time (US & Canada)
(GMT-05:00) Indiana (East)
(GMT-05:00) Lima
(GMT-05:00) Quito
(GMT-04:00) Atlantic Time (Canada)
(GMT-04:00) Caracas
(GMT-04:00) Georgetown
(GMT-04:00) La Paz
(GMT-04:00) Puerto Rico
(GMT-04:00) Santiago
(GMT-03:30) Newfoundland
(GMT-03:00) Brasilia
(GMT-03:00) Buenos Aires
(GMT-03:00) Greenland
(GMT-03:00) Montevideo
(GMT-02:00) Mid-Atlantic
(GMT-01:00) Azores
(GMT-01:00) Cape Verde Is.
(GMT+00:00) Casablanca
(GMT+00:00) Dublin
(GMT+00:00) Edinburgh
(GMT+00:00) Lisbon
(GMT+00:00) London
(GMT+00:00) Monrovia
(GMT+00:00) UTC
(GMT+01:00) Amsterdam
(GMT+01:00) Belgrade
(GMT+01:00) Berlin
(GMT+01:00) Bern
(GMT+01:00) Bratislava
(GMT+01:00) Brussels
(GMT+01:00) Budapest
(GMT+01:00) Copenhagen
(GMT+01:00) Ljubljana
(GMT+01:00) Madrid
(GMT+01:00) Paris
(GMT+01:00) Prague
(GMT+01:00) Rome
(GMT+01:00) Sarajevo
(GMT+01:00) Skopje
(GMT+01:00) Stockholm
(GMT+01:00) Vienna
(GMT+01:00) Warsaw
(GMT+01:00) West Central Africa
(GMT+01:00) Zagreb
(GMT+01:00) Zurich
(GMT+02:00) Athens
(GMT+02:00) Bucharest
(GMT+02:00) Cairo
(GMT+02:00) Harare
(GMT+02:00) Helsinki
(GMT+02:00) Jerusalem
(GMT+02:00) Kaliningrad
(GMT+02:00) Kyiv
(GMT+02:00) Pretoria
(GMT+02:00) Riga
(GMT+02:00) Sofia
(GMT+02:00) Tallinn
(GMT+02:00) Vilnius
(GMT+03:00) Baghdad
(GMT+03:00) Istanbul
(GMT+03:00) Kuwait
(GMT+03:00) Minsk
(GMT+03:00) Moscow
(GMT+03:00) Nairobi
(GMT+03:00) Riyadh
(GMT+03:00) St. Petersburg
(GMT+03:30) Tehran
(GMT+04:00) Abu Dhabi
(GMT+04:00) Baku
(GMT+04:00) Muscat
(GMT+04:00) Samara
(GMT+04:00) Tbilisi
(GMT+04:00) Volgograd
(GMT+04:00) Yerevan
(GMT+04:30) Kabul
(GMT+05:00) Ekaterinburg
(GMT+05:00) Islamabad
(GMT+05:00) Karachi
(GMT+05:00) Tashkent
(GMT+05:30) Chennai
(GMT+05:30) Kolkata
(GMT+05:30) Mumbai
(GMT+05:30) New Delhi
(GMT+05:30) Sri Jayawardenepura
(GMT+05:45) Kathmandu
(GMT+06:00) Almaty
(GMT+06:00) Astana
(GMT+06:00) Dhaka
(GMT+06:00) Urumqi
(GMT+06:30) Rangoon
(GMT+07:00) Bangkok
(GMT+07:00) Hanoi
(GMT+07:00) Jakarta
(GMT+07:00) Krasnoyarsk
(GMT+07:00) Novosibirsk
(GMT+08:00) Beijing
(GMT+08:00) Chongqing
(GMT+08:00) Hong Kong
(GMT+08:00) Irkutsk
(GMT+08:00) Kuala Lumpur
(GMT+08:00) Perth
(GMT+08:00) Singapore
(GMT+08:00) Taipei
(GMT+08:00) Ulaanbaatar
(GMT+09:00) Osaka
(GMT+09:00) Sapporo
(GMT+09:00) Seoul
(GMT+09:00) Tokyo
(GMT+09:00) Yakutsk
(GMT+09:30) Adelaide
(GMT+09:30) Darwin
(GMT+10:00) Brisbane
(GMT+10:00) Canberra
(GMT+10:00) Guam
(GMT+10:00) Hobart
(GMT+10:00) Melbourne
(GMT+10:00) Port Moresby
(GMT+10:00) Sydney
(GMT+10:00) Vladivostok
(GMT+11:00) Magadan
(GMT+11:00) New Caledonia
(GMT+11:00) Solomon Is.
(GMT+11:00) Srednekolymsk
(GMT+12:00) Auckland
(GMT+12:00) Fiji
(GMT+12:00) Kamchatka
(GMT+12:00) Marshall Is.
(GMT+12:00) Wellington
(GMT+12:45) Chatham Is.
(GMT+13:00) Nuku'alofa
(GMT+13:00) Samoa
(GMT+13:00) Tokelau Is.
tags :
Cancer
entities :
Takeda pharmaceutical company limited
save search
Non-Small Cell Lung Cancer (NSCLC) Market to Reach $29.95 Billion by 2028, Fueled by Advances in Therapy and Diagnostics
Published:
2024-02-22
(Crawled : 01:00)
- prnewswire.com
GLAXF
|
$20.2
-14.18%
510
|
Health Technology
|
-5.87%
|
O:
0.14%
H:
0.0%
C:
-0.0%
SNYNF
|
News
|
$92.116
-2.18%
2.3K
|
Health Technology
|
-3.13%
|
O:
0.26%
H:
1.36%
C:
1.36%
AZNCF
|
$135.305
-4.19%
1.1K
|
Health Technology
|
6.54%
|
O:
-0.85%
H:
1.12%
C:
0.43%
NVSEF
|
News
|
$93.6375
6.88%
82K
|
Health Technology
|
-8.14%
|
O:
0.92%
H:
0.0%
C:
0.0%
UCBJY
|
$63.31
-4.38%
9.4K
|
Manufacturing
|
25.87%
|
O:
1.46%
H:
0.44%
C:
0.44%
ALPMY
|
News
|
$9.34
-1.11%
690K
|
Manufacturing
|
-16.01%
|
O:
-0.27%
H:
0.0%
C:
-1.17%
TAK
|
$13.15
-0.61%
0.0%
1.6M
|
Health Technology
|
-10.79%
|
O:
-0.2%
H:
0.14%
C:
-0.48%
NVS
|
News
|
$93.08
-0.13%
0.86%
1.2M
|
Health Technology
|
-9.24%
|
O:
-0.06%
H:
0.46%
C:
0.29%
GSK
|
$39.6
-0.88%
0.0%
2.8M
|
Health Technology
|
-5.58%
|
O:
-0.69%
H:
1.42%
C:
1.22%
LLY
|
News
|
$750.77
0.54%
-0.04%
3.1M
|
Health Technology
|
0.65%
|
O:
2.37%
H:
1.51%
C:
0.79%
BMY
|
$47.84
-0.87%
-0.02%
12M
|
Health Technology
|
-5.21%
|
O:
-0.65%
H:
1.63%
C:
1.48%
ABBV
|
$164.25
1.05%
-0.76%
4M
|
Health Technology
|
-6.85%
|
O:
-0.88%
H:
1.46%
C:
1.13%
SNY
|
News
|
$46.125
0.71%
0.7%
3.7M
|
Health Technology
|
-2.16%
|
O:
1.67%
H:
0.0%
C:
0.0%
AZN
|
$68.53
0.39%
0.39%
3.7M
|
Health Technology
|
4.88%
|
O:
-2.81%
H:
2.08%
C:
1.38%
AMGN
|
$264.07
-0.59%
-0.59%
2.2M
|
Health Technology
|
-5.83%
|
O:
-0.35%
H:
1.15%
C:
0.96%
lung
reach
cancer
cell
diagnostics
therapy
market
Blood Cancer Drugs Market Report 2023: Reveals Striking Growth Prospects with a Surge in R&D Activities - Long-term Forecasts to 2028 and 2033
Published:
2024-02-06
(Crawled : 00:00)
- prnewswire.com
ALPMF
|
News
|
$9.594
43.47%
2.2K
|
Health Technology
|
-13.72%
|
O:
-1.53%
H:
0.0%
C:
0.0%
AZNCF
|
$135.305
-4.19%
1.1K
|
Health Technology
|
1.09%
|
O:
-0.37%
H:
0.0%
C:
0.0%
NVSEF
|
News
|
$93.6375
6.88%
82K
|
Health Technology
|
-8.98%
|
O:
0.41%
H:
0.0%
C:
0.0%
UCBJY
|
$63.31
-4.38%
9.4K
|
Manufacturing
|
37.02%
|
O:
1.71%
H:
1.28%
C:
0.94%
ALPMY
|
News
|
$9.34
-1.11%
690K
|
Manufacturing
|
-14.23%
|
O:
0.28%
H:
0.18%
C:
0.0%
TAK
|
$13.15
-0.61%
0.0%
1.6M
|
Health Technology
|
-7.13%
|
O:
0.07%
H:
0.42%
C:
0.07%
NVS
|
News
|
$93.08
-0.13%
0.86%
1.2M
|
Health Technology
|
-10.28%
|
O:
0.09%
H:
0.39%
C:
-0.36%
JNJ
|
News
|
$144.77
0.22%
-0.01%
9.3M
|
Health Technology
|
-7.04%
|
O:
1.47%
H:
0.0%
C:
0.0%
LLY
|
News
|
$750.77
0.54%
-0.04%
3.1M
|
Health Technology
|
6.49%
|
O:
0.76%
H:
4.31%
C:
2.11%
BMY
|
$47.84
-0.87%
-0.02%
12M
|
Health Technology
|
-2.03%
|
O:
-0.14%
H:
0.35%
C:
-1.12%
ABBV
|
$164.25
1.05%
-0.76%
4M
|
Health Technology
|
-3.96%
|
O:
1.48%
H:
0.0%
C:
0.0%
VRTX
|
$393.1
-0.27%
-0.27%
880K
|
Health Technology
|
-5.53%
|
O:
0.15%
H:
2.4%
C:
0.56%
SNY
|
News
|
$46.125
0.71%
0.7%
3.7M
|
Health Technology
|
-0.9%
|
O:
1.33%
H:
0.0%
C:
0.0%
JAZZ
|
News
|
$107.15
-1.61%
-1.63%
590K
|
Health Technology
|
-14.12%
|
O:
-0.02%
H:
0.0%
C:
-1.4%
AZN
|
$68.53
0.39%
0.39%
3.7M
|
Health Technology
|
1.83%
|
O:
-0.4%
H:
0.19%
C:
-0.33%
AMGN
|
$264.07
-0.59%
-0.59%
2.2M
|
Health Technology
|
-15.55%
|
O:
-0.18%
H:
0.0%
C:
-6.22%
report
cancer
blood
growth
market
United States Endometrial Cancer Research Report 2023
Published:
2024-02-02
(Crawled : 10:00)
- prnewswire.com
TAK
|
$13.15
-0.61%
0.0%
1.6M
|
Health Technology
|
-8.55%
|
O:
0.21%
H:
0.49%
C:
-0.9%
NVS
|
News
|
$93.08
-0.13%
0.86%
1.2M
|
Health Technology
|
-11.63%
|
O:
-0.5%
H:
0.26%
C:
-1.03%
report
cancer
research
Exelixis Announces Detailed Results of Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer Presented at ASCO GU 2024
Published:
2024-01-25
(Crawled : 22:00)
- biospace.com/
TAK
|
$13.15
-0.61%
0.0%
1.6M
|
Health Technology
|
-10.42%
|
O:
-0.27%
H:
0.07%
C:
-0.07%
EXEL
|
$22.875
0.24%
0.24%
2.8M
|
Health Technology
|
4.14%
|
O:
0.14%
H:
1.4%
C:
-0.23%
ntact-02
asco
cancer
trial
results
FRUZAQLA™ (fruquintinib) Now Available from Onco360 for the Treatment of Adult Patients with Metastatic Colorectal Cancer (mCRC)
Published:
2023-11-21
(Crawled : 18:00)
- biospace.com/
TAK
|
$13.15
-0.61%
0.0%
1.6M
|
Health Technology
|
-6.14%
|
O:
0.07%
H:
0.57%
C:
0.0%
cancer
treatment
Kadcyla Leads the Global Antibody Drug Conjugates Market with Extensive Use in Breast Cancer Treatment
Published:
2023-11-01
(Crawled : 18:00)
- prnewswire.com
ALPMY
|
News
|
$9.34
-1.11%
690K
|
Manufacturing
|
-23.18%
|
O:
-1.46%
H:
3.67%
C:
3.26%
ZYME
|
$8.86
-0.78%
-0.79%
370K
|
Health Technology
|
26.07%
|
O:
1.14%
H:
0.42%
C:
-0.7%
TAK
|
$13.15
-0.61%
0.0%
1.6M
|
Health Technology
|
-3.66%
|
O:
1.03%
H:
0.73%
C:
0.58%
ADCT
|
$4.96
11.71%
1.41%
1.2M
|
Health Technology
|
561.6%
|
O:
-0.16%
H:
6.42%
C:
4.49%
ABBV
|
$164.25
1.05%
-0.76%
4M
|
Health Technology
|
15.29%
|
O:
-0.86%
H:
0.0%
C:
0.0%
STRO
M
|
$3.78
-4.06%
-4.23%
720K
|
Health Technology
|
47.29%
|
O:
0.39%
H:
3.86%
C:
3.86%
IMGN
|
$31.23
0.03%
49M
|
Health Technology
|
109.1%
|
O:
5.09%
H:
5.48%
C:
-1.27%
GILD
|
$66.94
-0.55%
-0.55%
5.3M
|
Health Technology
|
-16.54%
|
O:
-0.47%
H:
1.88%
C:
1.78%
EXEL
|
$22.875
0.24%
0.24%
2.8M
|
Health Technology
|
9.54%
|
O:
-2.62%
H:
1.17%
C:
-1.66%
drug
antibody
breast
cancer
treatment
global
market
Exelixis and Ipsen Announce Positive Results from Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer
Published:
2023-08-21
(Crawled : 05:00)
- globenewswire.com
TAK
|
$13.15
-0.61%
0.0%
1.6M
|
Health Technology
|
-12.45%
|
O:
-0.4%
H:
0.6%
C:
0.47%
EXEL
|
$22.875
0.24%
0.24%
2.8M
|
Health Technology
|
9.12%
|
O:
0.28%
H:
1.32%
C:
0.99%
ntact-02
positive
cancer
trial
results
Global Cancer Therapies Strategic Business Report 2023: Industry Focuses on New Approaches to Treat Cancer
Published:
2023-06-27
(Crawled : 01:00)
- prnewswire.com
GLAXF
|
$20.2
-14.18%
510
|
Health Technology
|
11.2%
|
O:
-1.1%
H:
0.0%
C:
0.0%
TAK
|
$13.15
-0.61%
0.0%
1.6M
|
Health Technology
|
-16.61%
|
O:
-0.95%
H:
0.19%
C:
-0.32%
PFE
A
|
$25.42
-1.05%
-0.04%
44M
|
Health Technology
|
-31.09%
|
O:
0.19%
H:
0.11%
C:
-1.46%
NVS
|
News
|
$93.08
-0.13%
0.86%
1.2M
|
Health Technology
|
-6.46%
|
O:
-0.01%
H:
0.16%
C:
-0.32%
JNJ
|
News
|
$144.77
0.22%
-0.01%
9.3M
|
Health Technology
|
-11.53%
|
O:
0.03%
H:
0.12%
C:
-0.24%
GSK
|
$39.6
-0.88%
0.0%
2.8M
|
Health Technology
|
9.18%
|
O:
-0.91%
H:
0.56%
C:
-0.5%
LLY
|
News
|
$750.77
0.54%
-0.04%
3.1M
|
Health Technology
|
65.82%
|
O:
2.15%
H:
1.18%
C:
0.43%
BMY
|
$47.84
-0.87%
-0.02%
12M
|
Health Technology
|
-25.51%
|
O:
-0.06%
H:
0.46%
C:
0.0%
AZN
|
$68.53
0.39%
0.39%
3.7M
|
Health Technology
|
-4.83%
|
O:
-0.21%
H:
0.42%
C:
0.13%
report
business
cancer
treat
global
Takeda and HUTCHMED Announce Marketing Authorization Application of Fruquintinib for Previously Treated Metastatic Colorectal Cancer Validated by the European Medicines Agency
Published:
2023-06-15
(Crawled : 14:20)
- globenewswire.com
TAK
|
$13.15
-0.61%
0.0%
1.6M
|
Health Technology
|
-18.27%
|
O:
-0.31%
H:
0.78%
C:
0.69%
HCM
|
$16.45
-1.38%
-1.4%
290K
|
Health Technology
|
34.84%
|
O:
2.46%
H:
9.6%
C:
5.6%
authorization
cancer
application
Global Peptide Therapeutics Market Report 2023: Increasing Prevalence of Cancer and Metabolic Disorders Drives Growth
Published:
2023-06-08
(Crawled : 02:00)
- prnewswire.com
AZNCF
|
$135.305
-4.19%
1.1K
|
Health Technology
|
-7.89%
|
O:
0.07%
H:
0.0%
C:
-1.7%
NVSEF
|
News
|
$93.6375
6.88%
82K
|
Health Technology
|
14.25%
|
O:
1.32%
H:
0.0%
C:
-0.62%
TAK
|
$13.15
-0.61%
0.0%
1.6M
|
Health Technology
|
-18.27%
|
O:
-0.62%
H:
0.88%
C:
0.81%
NVS
|
News
|
$93.08
-0.13%
0.86%
1.2M
|
Health Technology
|
-5.5%
|
O:
1.26%
H:
1.08%
C:
0.91%
GSK
|
$39.6
-0.88%
0.0%
2.8M
|
Health Technology
|
15.25%
|
O:
0.41%
H:
0.68%
C:
0.64%
LLY
|
News
|
$750.77
0.54%
-0.04%
3.1M
|
Health Technology
|
72.05%
|
O:
-0.11%
H:
2.66%
C:
2.24%
BMY
|
$47.84
-0.87%
-0.02%
12M
|
Health Technology
|
-25.94%
|
O:
0.28%
H:
0.42%
C:
-0.05%
BNTX
|
$86.42
0.09%
0.09%
1.2M
|
Health Technology
|
-21.09%
|
O:
0.39%
H:
0.15%
C:
-0.79%
AZN
|
$68.53
0.39%
0.39%
3.7M
|
Health Technology
|
-6.88%
|
O:
-0.23%
H:
1.83%
C:
1.52%
AMGN
|
$264.07
-0.59%
-0.59%
2.2M
|
Health Technology
|
20.65%
|
O:
0.0%
H:
0.28%
C:
-0.23%
metabolic
report
cancer
global
therapeutics
growth
market
Targeted Therapy Global Market Report 2023: Increasing Prevalence of Cancer Drives Growth
Published:
2023-05-15
(Crawled : 17:00)
- prnewswire.com
GNMSF
|
$285.11
3.83%
420
|
Health Technology
|
-33.14%
|
O:
0.24%
H:
0.66%
C:
0.66%
NVSEF
|
News
|
$93.6375
6.88%
82K
|
Health Technology
|
7.89%
|
O:
-1.1%
H:
0.0%
C:
0.0%
TAK
|
$13.15
-0.61%
0.0%
1.6M
|
Health Technology
|
-19.72%
|
O:
0.61%
H:
0.3%
C:
0.24%
NVS
|
News
|
$93.08
-0.13%
0.86%
1.2M
|
Health Technology
|
-9.75%
|
O:
0.2%
H:
0.13%
C:
-0.22%
GSK
|
$39.6
-0.88%
0.0%
2.8M
|
Health Technology
|
8.4%
|
O:
0.27%
H:
0.6%
C:
0.41%
SNY
|
News
|
$46.125
0.71%
0.7%
3.7M
|
Health Technology
|
-14.75%
|
O:
0.38%
H:
0.0%
C:
0.0%
GMAB
|
$28.51
-3.13%
-3.23%
360K
|
Health Technology
|
-31.57%
|
O:
0.38%
H:
0.91%
C:
0.69%
AMGN
|
$264.07
-0.59%
-0.59%
2.2M
|
Health Technology
|
14.59%
|
O:
0.14%
H:
0.28%
C:
0.11%
report
cancer
global
therapy
growth
market
HUTCHMED Completes Rolling Submission of NDA to U.S. FDA for Fruquintinib for the Treatment of Refractory Metastatic Colorectal Cancer
Published:
2023-03-31
(Crawled : 01:00)
- globenewswire.com
TAK
|
$13.15
-0.61%
0.0%
1.6M
|
Health Technology
|
-19.57%
|
O:
0.0%
H:
0.92%
C:
0.8%
HCM
|
$16.45
-1.38%
-1.4%
290K
|
Health Technology
|
22.76%
|
O:
-1.19%
H:
2.04%
C:
-1.66%
fda
cancer
treatment
submission
Endometriosis Drugs Global Market Report 2023: Emerging Treatments for Endometriosis & Endometrial Cancer Present Opportunities
Published:
2023-03-11
(Crawled : 04:20)
- prnewswire.com
ALPMF
|
News
|
$9.594
43.47%
2.2K
|
Health Technology
|
Email alert
Add to watchlist
TAK
|
$13.15
-0.61%
0.0%
1.6M
|
Health Technology
|
Email alert
Add to watchlist
AZNCF
|
$135.305
-4.19%
1.1K
|
Health Technology
|
Email alert
Add to watchlist
OBSV
|
$0.1018
-15.52%
-18.95%
8.2M
|
Health Technology
|
Email alert
Add to watchlist
AZN
|
$68.53
0.39%
0.39%
3.7M
|
Health Technology
|
Email alert
Add to watchlist
ABBV
|
$164.25
1.05%
-0.76%
4M
|
Health Technology
|
Email alert
Add to watchlist
ALPMY
|
News
|
$9.34
-1.11%
690K
|
Manufacturing
|
Email alert
Add to watchlist
global
report
cancer
market
Global Head And Neck Cancer Therapeutics Market Report 2022: Sector to Reach $2.5 Billion by 2028 at a 12.3% CAGR
Published:
2023-01-12
(Crawled : 22:00)
- prnewswire.com
SNYNF
|
News
|
$92.116
-2.18%
2.3K
|
Health Technology
|
-6.69%
|
O:
-0.13%
H:
0.76%
C:
0.76%
AZNCF
|
$135.305
-4.19%
1.1K
|
Health Technology
|
-2.42%
|
O:
2.77%
H:
0.63%
C:
0.63%
TAK
|
$13.15
-0.61%
0.0%
1.6M
|
Health Technology
|
-16.45%
|
O:
0.13%
H:
2.35%
C:
2.16%
LLY
|
News
|
$750.77
0.54%
-0.04%
3.1M
|
Health Technology
|
109.06%
|
O:
0.13%
H:
1.04%
C:
0.57%
SNY
|
News
|
$46.125
0.71%
0.7%
3.7M
|
Health Technology
|
-4.66%
|
O:
1.89%
H:
0.0%
C:
0.0%
AZN
|
$68.53
0.39%
0.39%
3.7M
|
Health Technology
|
-2.59%
|
O:
1.27%
H:
0.78%
C:
0.15%
global
report
therapeutics
cancer
market
Ipsen Provides Update On Phase III CONTACT-01 Trial Evaluating Cabozantinib in Combination With Atezolizumab in Patients With Metastatic Non-small Cell Lung Cancer Previously Treated With Immunotherapy and Chemotherapy
Published:
2022-12-08
(Crawled : 23:00)
- biospace.com/
TAK
|
$13.15
-0.61%
0.0%
1.6M
|
Health Technology
|
-10.48%
|
O:
-0.07%
H:
1.09%
C:
1.09%
ntact-01
lung
immunotherapy
trial
update
cancer
Exelixis Provides Update on Phase 3 CONTACT-01 Trial Evaluating Cabozantinib in Combination with Atezolizumab in Patients with Metastatic Non-Small Cell Lung Cancer Previously Treated with Immunotherapy and Chemotherapy
Published:
2022-12-08
(Crawled : 22:00)
- biospace.com/
TAK
|
$13.15
-0.61%
0.0%
1.6M
|
Health Technology
|
-10.48%
|
O:
-0.07%
H:
1.09%
C:
1.09%
EXEL
|
$22.875
0.24%
0.24%
2.8M
|
Health Technology
|
40.83%
|
O:
0.0%
H:
1.59%
C:
1.04%
ntact-01
lung
immunotherapy
trial
update
cancer
Global Cancer Therapies Market Report 2022: Market to Reach $209.2 Billion by 2026 - Industry Focuses on New Approaches to Treat Cancer
Published:
2022-08-03
(Crawled : 19:00)
- prnewswire.com
GLAXF
|
$20.2
-14.18%
510
|
Health Technology
|
-1.46%
|
O:
-1.22%
H:
1.8%
C:
1.8%
AZNCF
|
$135.305
-4.19%
1.1K
|
Health Technology
|
3.84%
|
O:
2.52%
H:
0.0%
C:
-0.19%
NVSEF
|
News
|
$93.6375
6.88%
82K
|
Health Technology
|
28.56%
|
O:
-2.88%
H:
0.0%
C:
-0.21%
TAK
|
$13.15
-0.61%
0.0%
1.6M
|
Health Technology
|
-5.33%
|
O:
-0.29%
H:
0.72%
C:
0.58%
PFE
A
|
$25.42
-1.05%
-0.04%
44M
|
Health Technology
|
-49.02%
|
O:
0.08%
H:
0.29%
C:
-0.08%
NVS
|
News
|
$93.08
-0.13%
0.86%
1.2M
|
Health Technology
|
9.69%
|
O:
0.2%
H:
0.44%
C:
0.24%
JNJ
|
News
|
$144.77
0.22%
-0.01%
9.3M
|
Health Technology
|
-16.1%
|
O:
1.4%
H:
0.0%
C:
0.0%
GSK
|
$39.6
-0.88%
0.0%
2.8M
|
Health Technology
|
-2.99%
|
O:
0.27%
H:
0.1%
C:
-0.81%
LLY
|
News
|
$750.77
0.54%
-0.04%
3.1M
|
Health Technology
|
139.23%
|
O:
-1.16%
H:
0.02%
C:
-1.42%
BMY
|
$47.84
-0.87%
-0.02%
12M
|
Health Technology
|
-33.88%
|
O:
-0.27%
H:
0.22%
C:
-0.92%
AZN
|
$68.53
0.39%
0.39%
3.7M
|
Health Technology
|
4.51%
|
O:
1.13%
H:
0.35%
C:
0.35%
global
report
cancer
market
Exelixis Announces Cabozantinib in Combination with Nivolumab and Ipilimumab Significantly Improved Progression-Free Survival in Phase 3 COSMIC-313 Pivotal Trial in Patients with Previously Untreated Advanced Kidney Cancer
Published:
2022-07-11
(Crawled : 13:00)
- biospace.com/
TAK
|
$13.15
-0.61%
0.0%
1.6M
|
Health Technology
|
-8.17%
|
O:
0.91%
H:
0.35%
C:
-0.21%
EXEL
|
$22.875
0.24%
0.24%
2.8M
|
Health Technology
|
7.04%
|
O:
1.67%
H:
0.0%
C:
-5.67%
osmic-313
kidney
trial
cancer
phase 3
nivolumab
Exelixis Announces Detailed Results from Urothelial Carcinoma and Non-Small Cell Lung Cancer Cohorts of the COSMIC-021 Trial at ASCO 2022
Published:
2022-05-26
(Crawled : 00:00)
- biospace.com/
TAK
|
$13.15
-0.61%
0.0%
1.6M
|
Health Technology
|
-11.89%
|
O:
-0.17%
H:
0.0%
C:
0.0%
EXEL
|
$22.875
0.24%
0.24%
2.8M
|
Health Technology
|
29.28%
|
O:
0.11%
H:
0.0%
C:
0.0%
osmic-021
trial
asco
results
cancer
urothelial carcinoma
Exelixis’ Partner Ipsen Receives European Commission Approval for CABOMETYX® (cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer
Published:
2022-05-03
(Crawled : 18:00)
- biospace.com/
TAK
|
$13.15
-0.61%
0.0%
1.6M
|
Health Technology
|
-9.25%
|
O:
0.41%
H:
0.0%
C:
0.0%
BMY
|
$47.84
-0.87%
-0.02%
12M
|
Health Technology
|
-35.72%
|
O:
0.36%
H:
0.0%
C:
0.0%
EXEL
|
$22.875
0.24%
0.24%
2.8M
|
Health Technology
|
1.61%
|
O:
0.09%
H:
1.54%
C:
-0.44%
cabometyx
approval
cancer
← Previous
1
2
Next →
Gainers vs Losers
56%
44%
Top 10 Gainers
INVO
|
$1.76
131.58%
56.82%
230M
|
Health Technology
SINT
|
$0.0365
59.39%
37.26%
470M
|
Health Technology
WISA
4
|
$9.19
50.66%
33.7%
65M
|
Electronic Technology
EDBL
|
News
|
$6.73
47.91%
32.39%
13M
|
GCTK
|
$0.715
36.27%
26.62%
640K
|
Manufacturing
TCON
|
$2.33
36.26%
26.61%
2M
|
Health Technology
TIRX
|
$0.48
6.43%
24.58%
4.8M
|
KZIA
|
$0.38
30.58%
23.42%
300K
|
Health Technology
VNDA
|
News
|
$5.23
29.14%
22.56%
24M
|
Health Technology
ATNF
|
$1.91
29.05%
22.51%
310K
|
Your saved searches
Save your searches and get alerts when important news are released.